The origin of the Johns Hopkins Drug Discovery Program can be traced back to the NeuroTranslational Drug Discovery program, created in 2009 as an integral part of the Brain Science Institute under the leadership of Drs. Jack Griffin, Janice E. Clements, Richard Huganir, and Jeffrey Rothstein. The program was conceived with the mission of translating new discoveries in neuroscience at Johns Hopkins into novel therapeutics.
A multidisciplinary team of scientists with industrial experience in drug discovery research was recruited for the program to fulfill its mission. Since the inception, the program has provided the Johns Hopkins neuroscience community with core expertise in drug discovery research including medicinal chemistry, screening assay development, drug metabolism and pharmacokinetics, and animal pharmacology/toxicology. The collaborative efforts have led to the launch of a number of new drug discovery projects with real potential for impacting the lives of patients suffering from neurological disorders.
Given the program’s initial success, the leadership at Johns Hopkins Medicine has made an executive decision to expand the program’s mission beyond CNS disorders. In 2015, it was renamed to the Johns Hopkins Drug Discovery Program in light of the expanded therapeutic areas pursued by the program. The Johns Hopkins Drug Discovery Program continues to work with the researchers across Johns Hopkins to research and develop tomorrow’s therapeutics for a wide range of human disorders.